Further, the highest CEACAM1 and PD-L1 levels were observed in the treatment-resistant tumors; CEACAM1 and PD-L1 levels were also elevated on the treatment-naive tumor-associated monocytic cells relative to the healthy donors (Fig. 4c, e). This evidence concerns the gene CEACAM1 and neoplasm.